Sign up for free insights newsletter
FS

Fresenius SE & Co KGaA ADR

FSNUYUnited States

Need professional-grade analysis? Visit stockanalysis.com

$12.82
+1.91%
End of day
Market Cap

$29.04B

P/E Ratio

N/A

Employees

N/A

Dividend Yield

220.00%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.52-0.500.74-0.24
Calmar-2.19-0.430.49-0.49
Sharpe-1.26-0.360.53-0.22
Omega0.740.961.150.99
Martin-6.89-0.600.97-1.52
Ulcer5.8231.2821.8921.00

Fresenius SE & Co KGaA ADR (FSNUY) Price Performance

Fresenius SE & Co KGaA ADR (FSNUY) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at $12.82, up 1.91% from the previous close.

Over the past year, FSNUY has traded between a low of $9.49 and a high of $22.45. The stock has gained 20.9% over this period. It is currently 42.9% below its 52-week high.

Fresenius SE & Co KGaA ADR has a market capitalization of $29.04B and a dividend yield of 220.00%.

About Fresenius SE & Co KGaA ADR

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$22.45B
EBITDA
$2.52B
Profit Margin
5.09%
EPS (TTM)
0.59
Book Value
38.22

Technical Indicators

52 Week High
$33.93
52 Week Low
$9.49
50 Day MA
$14.43
200 Day MA
$13.84
Beta
0.91

Valuation

Trailing P/E
21.85
Forward P/E
4.36
Price/Sales
1.29
Price/Book
0.34
Enterprise Value
$19.08B